A total of 574 participants were randomly assigned and treated, with 383 switching to bictegravir/lenacapavir and 191 continuing B/F/TAF. The study population had a median age of 49 years and included 19% women, with 27% Black and 27% Hispanic or Latino participants.
What You Need to Know
Switching to bictegravir/lenacapavir maintained viral suppression through 48 weeks at rates comparable to continued B/F/TAF.
Adverse events, drug-related events, and discontinuation rates were similar between the investigational regimen and standard of care.
The combination of an integrase inhibitor with a capsid inhibitor introduces a novel STR option that could broaden switching strategies for people with virologically suppressed HIV.
At week 48, HIV-1 RNA of 50 copies/mL or more occurred in 1.3% of participants in the bictegravir/lenacapavir group and 1.0% in the B/F/TAF group, meeting the predefined criteria for noninferiority. Virologic suppression below 50 copies/mL was maintained in more than 90% of participants in both arms.
Immunologic outcomes were similar between groups, with small median changes in CD4 cell counts from baseline at week 48. Safety findings were also comparable, with overall adverse event rates of approximately 75% in both groups, the majority of which were mild or moderate. Drug-related adverse events were infrequent, serious events were rare, and discontinuations due to adverse events were low and identical between arms.
Reference
Meissner EG, Ramgopal M, Ruane PJ, et al. Phase 3 efficacy and safety of switch from B/F/TAF to single-tablet BIC/LEN in ARTISTRY-2. Abstract presented at: Conference on Retroviruses and Opportunistic Infections; February 22-25, 2026; Denver, CO.